Journal of Clinical Oncology

Vol. 44, Issue 19 Issue 19 2026
16
Articles

Articles in this Issue

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Arnaud Scherpereel, Paul Baas, Anna K. Nowak et al. Jul 01, 2026 pp. 1852-1852 10.1200/jco-26-01289

Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial

Cheng Yang, Qi Jia, Chenglong Zhao et al. Jul 01, 2026 pp. 1822-1832 10.1200/jco-25-02719

PURPOSE Limited efficacy of current treatments for chordoma calls for novel therapeutic options. Combination of immune checkpoint inhibitors and antiangiogenic drugs has altered th...

Canine Olfaction Combined With Bayesian Modeling for Multicancer Detection From Breath Samples: A Phase II Study in India

Sanjeev Kulgod, Basavaraj R. Patil, Shashidhar Kallappa et al. Jul 01, 2026 pp. 1774-1783 10.1200/jco-25-02310

PURPOSE Low-cost, acceptable, high-sensitivity triage tests are needed to address low cancer prevalence in population screening, particularly in low- and middle-income countries. B...

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer

Vedang Murthy, Priyamvada Maitre, Mahendra Pal et al. Jul 01, 2026 pp. 1812-1821 10.1200/jco-25-02093

PURPOSE To report the primary analysis of a multicenter, phase III randomized trial of adjuvant radiotherapy (RT) after chemotherapy and radical cystectomy (RC) in patients with hi...

Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia

William G. Wierda, Ching Ching Leow, Amy S. Ruppert et al. Jul 01, 2026 pp. 1847-1851 10.1200/jco-26-00304

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano et al. Jul 01, 2026 pp. 1852-1852 10.1200/jco-26-01302

Rethinking Optimal Therapy for Operable Pancreatic Cancer in the CASSANDRA Era

Fausto Petrelli, Lorenzo Dottorini Jul 01, 2026 pp. 1762-1766 10.1200/jco-25-02920

How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia

Vincent Levy, Sylvie Chevret Jul 01, 2026 pp. 1847-1847 10.1200/jco-25-03114

Bridging the Gap: Integrating External Beam Radiation Therapy Into the Management of Hepatocellular Carcinoma

Sunil W. Dutta, Naba Ali, Pretesh R. Patel et al. Jul 01, 2026 pp. 1757-1761 10.1200/jco-26-00521

Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial

Frank A. Vicini, Kathryn Winter, Gary M. Freedman et al. Jul 01, 2026 pp. 1798-1811 10.1200/jco-25-02465

PURPOSE For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduc...

Erratum: Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial

Cheng Yang, Qi Jia, Chenglong Zhao et al. Jul 01, 2026 pp. 1853-1853 10.1200/jco-26-01304

When the Nose Knows: Canine Olfaction and the Emerging Paradigm of Multicancer Detection

Shiran Shapira, Nadir Arber Jul 01, 2026 pp. 1751-1756 10.1200/jco-26-00688

Indistinguishable From Magic

Michael J. Slade Jul 01, 2026 pp. 1845-1846 10.1200/jco-25-02492

This piece looks at the challenges of day-to-day clinical practice in oncology through the lens of speculative fiction and how we struggle, as physicians and as patients, to tell the difference betwee...

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

Lara Stepan, Sahar Ansari, Jeremy S. Abramson et al. Jul 01, 2026 pp. 1767-1773 10.1200/jco-25-03051

We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleuce...

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort

Andrew M. Moon, Ted K. Yanagihara, Laura A. Dawson et al. Jul 01, 2026 pp. 1784-1797 10.1200/jco-25-02399

PURPOSE External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given...

Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies

Cassio Murilo Hidalgo-Filho, Valentina Santo, Eleonora Gariazzo et al. Jul 01, 2026 pp. 1833-1844 10.1200/jco-25-03026

Acquired resistance (AR) to immune checkpoint inhibitors (ICIs) remains a major obstacle to durable clinical benefit in non–small cell lung cancer (NSCLC). Emerging after initial responses, AR reflect...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page